主页 > 医药生命 >
【drug-news】大多数非甾体类抗炎药与心血管事件
The findings also support prior research linking rofecoxib (Vioxx) with adverse cardiovascular effects. After concerns first surfaced, the drug was pulled from the market in 2004. Valdecoxib, which was marketed as Bextra, was later withdrawn for similar reasons.
The experience with these two COX-2 inhibitors led many to question whether other selective and non-selective NSAIDs were safe, Dr. Daniel H. Solomon, from Brigham and Women's Hospital in Boston, and colleagues point out.
In a study of Medicare beneficiaries who were eligible for drug benefits from 1999 to 2004, Dr. Solomon's team assessed the occurrence of cardiovascular events (MI, stroke, heart failure, and cardiovascular death) in 76,082 new users of COX-2 inhibitors, 53,014 new users of nonselective NSAIDs, and 46,558 who didn't use either type of drug.
During 64,136 person-years of follow-up, 7262 cardiovascular events were logged, the report indicates.
Patient risk factors for cardiovascular events included age of 80 years or older, hypertension, prior MI, prior cardiovascular disease, rheumatoid arthritis, chronic obstructive pulmonary disease, and chronic renal disease.
Rofecoxib users had the highest event rates, while naproxen users had the lowest, even lower than nonusers. Further analysis showed that of the various NSAIDs evaluated, only rofecoxib and ibuprofen increased the risk of cardiovascular events across patient subgroups.
"These results should bolster physicians' and patients' confidence that most coxibs and nonselective NSAIDs are not associated with an elevated risk of cardiovascular events in many patient subgroups using typical doses," the authors conclude.
Arthritis Rheum 2008;59:1097-1104. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 NEW YORK (Reuters Health) Sept 04 - When used at standard doses, most NSAIDs do not increase the risk of MI, stroke, or other cardiovascular events, new research shows. However, when used on a daily basis, ibuprofen may increase the risk, according to a report in the August 15th issue of. Arthritis Care and Research
纽约（路透社 健康）九月四日－最新的研究显示：当应用标准计量时，大部分非甾体类抗炎药不会增加心肌梗塞、中风和其他心血管事件的风险。然而据八月十五日的一期Arthritis Care and Research的文章报道，如果每天应用的话布洛芬可能会增加这些风险。
The findings also support prior research linking rofecoxib (Vioxx) with adverse cardiovascular effects. After concerns first surfaced, the drug was pulled from the market in 2004. Valdecoxib, which was marketed as Bextra, was later withdrawn for similar reasons.
该研究也支持以前关于罗非考昔(Vioxx)与心血管副作用相关的结论。当首次出现副作用的报道后，该药在２００４年从市场上被召回。伐地考昔，其商品名为Bextra，随后也因为相似的原因被召回。
The experience with these two COX-2 inhibitors led many to question whether other selective and non-selective NSAIDs were safe, Dr. Daniel H. Solomon, from Brigham and Women's Hospital in Boston, and colleagues point out.
来自波士顿的Brigham女子医院的Daniel H. Solomon博士和他的同事指出：这两种ＣＯＸ－２抑制剂的经历导致很多人质疑其他的选择性和非选择性非甾体抗炎药的安全性。
In a study of Medicare beneficiaries who were eligible for drug benefits from 1999 to 2004, Dr. Solomon's team assessed the occurrence of cardiovascular events (MI, stroke, heart failure, and cardiovascular death) in 76,082 new users of COX-2 inhibitors, 53,014 new users of nonselective NSAIDs, and 46,558 who didn't use either type of drug.
在一个对１９９９至２００４年适宜应用该药的医疗保险受益人的研究中，Solomon博士的团队评估了７６０８２名新近应用了ＣＯＸ－２受体抑制剂，５３０１４名新近应用了非选择性非甾体抗炎药，和４６５５８名两类药物均没有应用的患者的心血管事件（心肌梗死，中风，心衰和心血管死亡）发生情况。
During 64,136 person-years of follow-up, 7262 cardiovascular events were logged, the report indicates.
报道指出：在64136位患者的随访期间，发生了7262心血管事件。
Patient risk factors for cardiovascular events included age of 80 years or older, hypertension, prior MI, prior cardiovascular disease, rheumatoid arthritis, chronic obstructive pulmonary disease, and chronic renal disease.
发生心血管事件的患者风险因子包括：年龄大于或等于８０岁，高血压，心肌梗死史，心血管疾病史，风湿性关节炎，慢性阻塞性肺病和慢性肾病。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-12-10 17:11
医学,生命科学网